# US 2021/0060320 A1 · Transdermal drug delivery system and method for using same

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0060320 A1
- Document ID: US20210060320A1
- Status: Published application
- Kind: A1
- Application number: 16/958,071
- Filed: 2018-12-27
- Published: 2021-03-04
- Earliest claimed: 2017-12-28
- Assignees: Nichiban Co., Ltd.; Senju USA, Inc.
- Applicants: Nichiban Co., Ltd.; Senju USA, Inc.
- Inventors: Teppei OSAKO; Koji KAWAHARA; Takahiro OGAWA; Akiharu ISOWAKI,; Tetsuo KIDA
- Web page: https://patentgrep.com/patent/US20210060320A1

## CPC

- A61F 9/007: Methods or devices for eye surgery
- A61M 37/0015: {by using microneedles}
- A61F 9/0008: {Introducing ophthalmic products into the ocular cavity or retaining products therein (putting in contact lenses A61F9/0061; introducing or retaining media in cavities of the body in general A61M31/00)}
- A61K 9/0021: {Intradermal administration, e.g. through microneedle arrays or needleless injectors}
- A61K 9/0048: {Eye, e.g. artificial tears}
- A61K 31/573: substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
- A61M 2037/0023: {Drug applicators using microneedles}
- A61M 2037/0046: {Solid microneedles}
- A61M 2037/0061: {Methods for using microneedles}
- A61F: FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS (dental prosthetics A61C)
- A61M: DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY (introducing media into or onto the bodies of animals A61D7/00; means for inserting tampons A61F13/26; devices for administering food or medicines orally A61J; containers for collecting, storing or administering blood or medical fluids A61J1/05); DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY (surgery A61B; chemical aspects of surgical articles A61L); DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR {(Electrotherapy, e.g. producing anaesthesia by the use of alternating or intermittent currents A61N1/36021)}
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

A method for administering a drug to a diseased portion is achieved in a short time and predominantly improves the administration amount (transdermal permeation amount) of the drug in treatment of eyelid disease or palpebral conjunctiva disease. The method for administering a drug for treatment of eyelid disease or palpebral conjunctiva disease includes a step of microneedle perforation by using a microneedle device into a tissue of the eyelid including a meibomian gland of a patient suffering from or suspected of having the disease, in which drug-containing coating is applied to at least a part of a surface of the microneedle, and the drug is a water-soluble drug.

## Claims

### Claim 1

A method for administering a drug for treatment of eyelid disease or palpebral conjunctiva disease, comprising
a step of conducting a microneedle perforation by using a microneedle device into a tissue of the eyelid including a meibomian gland of a patient that has been infected with or that may be infected with the disease,
wherein drug-containing coating is applied to at least a part of a surface of the microneedle, and
the drug is a water-soluble drug.

### Claim 2 (depends on 1)

The method according to claim 1, wherein the drug is at least a water-soluble steroid having an octanol/water distribution coefficient (log D) selectable in a range from −5 to 0.

### Claim 3 (depends on 1)

The method according to claim 1, wherein the drug is at least one water-soluble steroid selectable from the group consisting of dexamethasone sodium phosphate, dexamethasone metasulfobenzoate sodium, hydrocortisone sodium phosphate, hydrocortisone sodium succinate, prednisolone sodium phosphate, prednisolone sodium succinate, methylprednisolone sodium succinate, and betamethasone sodium phosphate.

### Claim 4 (depends on 1)

The method according to claim 1, wherein the drug-containing coating contains at least one kind of water-soluble polymer selectable from the group consisting of polyhydroxymethyl cellulose, polyhydroxypropyl methyl cellulose, polymethyl cellulose, hydroxyethyl cellulose, hydroxypropyl cellulose, hydroxypropyl methyl cellulose, carboxymethyl cellulose, carboxypropyl cellulose, dextran, polyethylene glycol, polyvinyl alcohol, polyvinyl pyrrolidone, pullulan, chondroitin sulfate or an ester salt thereof, and hyaluronic acid or a salt thereof.

### Claim 5 (depends on 1)

The method according to claim 1, wherein the step of conducting the microneedle perforation is a step of conducting a microneedle perforation into a surface of the eyelid skin or a surface of the palpebral conjunctiva.

### Claim 6 (depends on 1)

The method according to claim 1, wherein the step of conducting the microneedle perforation is a step of conducting a microneedle perforation for 1 second to 10 seconds.

### Claim 7 (depends on 1)

The method according to claim 1, further comprising a step of applying a vasoconstrictor to the tissue of the eyelid.

### Claim 8 (depends on 1)

The method according to claim 1, wherein the eyelid disease or the palpebral conjunctiva disease is at least one disease selectable from the group consisting of chalazion, blepharitis, meibomian gland dysfunction, allergic conjunctivitis, and vernal keratoconjunctivitis.

### Claim 9

A microneedle device for administering a drug for treatment of eyelid disease or palpebral conjunctiva disease to a tissue of the eyelid including a meibomian gland, comprising
a microneedle,
wherein coating containing the drug is applied to at least a part of a surface of the microneedle, and
the drug is a water-soluble drug.

### Claim 10 (depends on 9)

The microneedle device according to claim 9, wherein the microneedle device is a device for administering the drug through the eyelid skin or the palpebral conjunctiva.

### Claim 11

A microneedle device for administering a drug for treatment of eyelid disease or palpebral conjunctiva disease to a tissue of the eyelid including a meibomian gland through the eyelid skin or the palpebral conjunctiva, comprising
a microneedle,
wherein coating containing the drug is applied to at least a part of a surface of the microneedle, and
the drug is a water-soluble drug.

### Claim 12 (depends on 9)

The microneedle device according to claim 9, wherein the drug is at least a water-soluble steroid having an octanol/water distribution coefficient (log D) selectable in a range from −5 to 0.

### Claim 13 (depends on 9)

The microneedle device according to claim 9, wherein the drug is at least one water-soluble steroid selectable from the group consisting of dexamethasone sodium phosphate, dexamethasone metasulfobenzoate sodium, hydrocortisone sodium phosphate, hydrocortisone sodium succinate, prednisolone sodium phosphate, prednisolone sodium succinate, methylprednisolone sodium succinate, and betamethasone sodium phosphate.

### Claim 14 (depends on 9)

The microneedle device according to claim 9, wherein the coating contains at least one kind of water-soluble polymer selectable from the group consisting of polyhydroxymethyl cellulose, polyhydroxypropyl methyl cellulose, polymethyl cellulose, hydroxyethyl cellulose, hydroxypropyl cellulose, hydroxypropyl methyl cellulose, carboxymethyl cellulose, carboxypropyl cellulose, dextran, polyethylene glycol, polyvinyl alcohol, polyvinyl pyrrolidone, pullulan, chondroitin sulfate or an ester salt thereof, and hyaluronic acid or a salt thereof.

### Claim 15 (depends on 9)

The microneedle device according to claim 9, wherein the eyelid disease or the palpebral conjunctiva disease is at least one disease selectable from the group consisting of chalazion, blepharitis, meibomian gland dysfunction, allergic conjunctivitis, and vernal keratoconjunctivitis.

### Claim 16 (depends on 9)

The microneedle device according to claim 9, wherein the microneedle device is used for treatment of eye disease due to dysfunction of a tissue of the eyelid.

### Claim 17 (depends on 9)

The microneedle device according to claim 9, wherein the microneedle device is used for treatment of eye disease.

### Claim 18 (depends on 9)

The microneedle device according to claim 9, further comprising a microneedle array provided with the microneedle, wherein the microneedle array has an area of 0.01 cm2 or more and 1.20 cm2 or less.

### Claim 19 (depends on 9)

A method for treatment of eyelid disease or palpebral conjunctiva disease, comprising a step of making a microneedle in the microneedle device according to claim 9, perforated into the eyelid skin or a surface of the palpebral conjunctiva of a patient that has been infected with or that may be infected with disease.

### Claim 20 (depends on 19)

The method according to claim 19, wherein the step of conducting the microneedle perforation is a step of conducting a microneedle perforation for 1 second to 10 seconds.

### Claim 21 (depends on 19)

The method according to claim 19, further comprising a step of applying a vasoconstrictor to a tissue of the eyelid.

### Claim 22 (depends on 9)

A set for treatment of eyelid disease or palpebral conjunctiva disease, comprising: the microneedle device according to claim 9, and a drug product containing one or both of a support base for eyelid skin and a vasoconstrictor.
